Eli Lilly Pledges US$3 Billion Investment to Expand China Supply Chain
Eli Lilly has committed an additional US$3 billion investment in China over the next decade to enhance its local supply chain and manufacturing capabilities, anticipating approval for its drug orforglipron.
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (32/100)Sources
Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain
Eli Lilly has pledged an additional US$3 billion investment in China over the next decade to strengthen its local supply chain and manufacturing capabilities, deepening the footprint of foreign pharmaceutical giants in the world’s second-largest healthcare market. The move would bring the total cumulative investment of Eli Lilly, the world’s largest pharmaceutical company by market capitalisation, in China to nearly US$6 billion, according to a statement released on its WeChat account on...
By Themis Qi,Julie Zhang
Read full article →Eli Lilly to invest $3bn in China in anticipation of orforglipron approval
Read full article →Coverage Timeline
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Philippines Energy Secretary Confirms Diesel Cargo Arrival Amid Petronas Denial
just now
Philippine President Marcos Urges Unity, Warns Against Hoarding Amid Energy Crisis
just now
Marcos to decide on fuel excise tax cut or suspension by April 13
just now